Cardiovascular Drugs - GEN - Genetic Engineering and Biotechnology News

Cholesterol plaque in artery with Human heart anatomy. 3d illustration

Cardiovascular Drugs

New Heart Disease Therapeutic Target Identified

RNAi

StockWatch: Alnylam Basks in the Glow of Heart Drug’s Phase III Success

Ribonucleic acid strands [iStock / Getty Images Plus]

Cardiovascular Drugs

HAYA Is Developing Therapeutics Targeting Long Non-Coding RNAs

Atherosclerosis, artwork

Cardiovascular Drugs

Cellular Housekeeping Process May Protect against Atherosclerosis

Drug Discovery

Vikram Bajaj, PhD: “Innovation Doesn’t Come from Boston and San Francisco Alone”

Medication

Cardiovascular Disease

An App a Day Keeps the Doctor Away: Better Therapeutics Targets...

Cardiovascular Drugs

Merck & Co. to Acquire Acceleron for $11.5B

Measuring BP

Cardiovascular Drugs

Pulsing Ultrasound at Kidneys Can Lower Blood Pressure When Medications Don’t

Mutations in the gene APOC3 lower triglyceride levels in the blood and also significantly reduce a person's risk of coronary heart disease. [Susanna Hamilton

Cardiovascular Drugs

Prescribing the Right Blood Thinner May Pivot on a Genetic Test

Vein Atherosclerotic Plaque

Cardiovascular Drugs

Preclinical Study Shows Safety, Efficacy, and Durability of Lowering LDL-Cholesterol Levels...

3d illustration of a part of RNA chain from which the deoxyribonucleic acid or DNA is composed

Cardiovascular Drugs

RNA in Its DNA: Avidity Biosciences Combines mAb Selectivity, Oligonucleotide Precision

Cardiovascular Drugs

Bayer Approach to Partnerships, Pipelines, and Platforms

Cardiovascular Drugs

Bristol-Myers Squibb to Acquire MyoKardia for $13.1B, Expanding Cardiovascular Franchise

Cardiovascular Drugs

Old, Leaky Blood Vessels Modeled via Direct Reprogramming of Skin Cells

Vein Atherosclerotic Plaque

Cardiovascular Drugs

Heart Disease Therapeutics Could Arise from Newly Discovered Mutation

12 3...6 Page 1 of 6